- GSK-2110183C
-
- $2.00 / 1kg
-
2019-07-06
- CAS:1047644-62-1
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | GSK-2110183C Basic information |
| Product Name: | GSK-2110183C | | Synonyms: | Afuresertib(GSK2110183C);GSK 2110183C;GSK2110183C;GSK-2110183C;N-((S)-1-amino-3-(3-fluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide;Afuresertib, GSK-2110183, GSK-2110183B;Delitinib;9-dihydroxyaporphine | | CAS: | 1047644-62-1 | | MF: | C18H17Cl2FN4OS | | MW: | 427.32 | | EINECS: | 1592732-453-0 | | Product Categories: | Inhibitors | | Mol File: | 1047644-62-1.mol |  |
| | GSK-2110183C Chemical Properties |
| Boiling point | 535.1±50.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C, protect from light, stored under nitrogen | | solubility | DMSO:62.5(Max Conc. mg/mL);146.26(Max Conc. mM)
Ethanol:85.0(Max Conc. mg/mL);198.91(Max Conc. mM) | | pka | 13.03±0.46(Predicted) | | form | Powder |
| | GSK-2110183C Usage And Synthesis |
| Uses | Afuresertib is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma. | | Definition | ChEBI: N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide is a member of amphetamines. |
| | GSK-2110183C Preparation Products And Raw materials |
|